Axovant Sciences Ltd. (AXON) said that its investigational drug intepirdine did not meet its primary efficacy endpoints in the Phase 2b HEADWAY and pilot Phase 2 Gait and Balance studies. The company noted that the Intepirdine program will be discontinued based on the MINDSET, HEADWAY, and Gait and Balance study results.
from RTT - Biotech http://ift.tt/2AFxCK1
via IFTTT
No comments:
Post a Comment